TransTech Pharma and Forest Laboratories have entered into a license agreement for the development and commercialization of small molecule compounds discovered by TransTech. These compounds are functionally liver-selective Glucokinase Activators (GKAs), which represent a new class of glucose-lowering agents for the treatment of diabetes. TransTech will receive an upfront license payment of $50 million and is eligible to receive as much as $1.1 billion in upfront and milestone payments for the...